These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 12599782)

  • 1. [Detection and clinical significance of CYFRA21-1 in serum of laryngeal carcinoma patients].
    Luo R; Li G; Zhu C
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Jun; 16(6):289-91. PubMed ID: 12599782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of the novel tumor marker CYFRA21-1 in patients with esophageal cancer].
    Wang T; Zhang W; Liu Y
    Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1390-1. PubMed ID: 11930636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of CEA, SCC and Cyfra21-1 serum test in esophageal cancer].
    Mao YS; Zhang DC; Zhao XH; Wang LJ; Qi J; Li XX
    Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):457-60. PubMed ID: 14575569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnostic value of combined detection of CYFRA21-1 and TSGF in nasopharyngeal carcinoma].
    Huang L; Huang W; Chen Y
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Mar; 19(5):201-2. PubMed ID: 15934283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
    Li R; Li R; Wang Y
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Usefulness of CYFRA21-1 as a tumor marker of non-small-cell lung cancer].
    Tan Y; Zhang P; Zheng C
    Zhonghua Zhong Liu Za Zhi; 1999 Jul; 21(4):287-9. PubMed ID: 11776818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
    Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
    Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.
    Uenishi T; Yamazaki O; Tanaka H; Takemura S; Yamamoto T; Tanaka S; Nishiguchi S; Kubo S
    Ann Surg Oncol; 2008 Feb; 15(2):583-9. PubMed ID: 17955299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum CYFRA21-1 as a prognostic marker for patients with undifferentiated nasopharyngeal carcinoma.
    Zhu WQ; Yu JM; Sun XD; Xie P; Kong L
    Biomarkers; 2010 Nov; 15(7):602-7. PubMed ID: 20726807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Kameyama M; Suehiro S
    Ann Thorac Surg; 2007 Jan; 83(1):216-21. PubMed ID: 17184666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased serum midkine concentration as a possible tumor marker in patients with superficial esophageal cancer.
    Shimada H; Nabeya Y; Okazumi S; Matsubara H; Kadomatsu K; Muramatsu T; Ikematsu S; Sakuma S; Ochiai T
    Oncol Rep; 2003; 10(2):411-4. PubMed ID: 12579281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
    Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYFRA21-1 as a serum tumor marker for follow-up patients with squamous cell lung carcinoma and oropharynx squamous cell carcinoma.
    Liu L; Liu B; Zhu LL; Li Y
    Biomark Med; 2013 Aug; 7(4):591-9. PubMed ID: 23905896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma.
    Al-Shagahin H; Alkotyfan K; Müller HH; Sesterhenn AM; Werner JA
    Anticancer Res; 2009 Aug; 29(8):3421-5. PubMed ID: 19661367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies of serum markers in patients with interstitial pneumonia/pulmonary fibrosis complicated with collagen diseases: clinical evaluation of CYFRA21-1].
    Suzuki A; Masuda T; Koito N; Suzuki T; Mita S; Matsuoka Y; Irimajiri S
    Ryumachi; 1996 Dec; 36(6):837-43. PubMed ID: 9122823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma.
    Yi Y; Li B; Wang Z; Sun H; Gong H; Zhang Z
    Biomarkers; 2009 Nov; 14(7):480-5. PubMed ID: 19863186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
    Hang ZQ; Zheng MF; Huang JH
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.